Stock Code: 000028/200028 Notice No.: 2022-36Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Semi-Annual Report 2022
I. Important Notice
The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors shouldcarefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and ShenzhenStock Exchange Website etc., appointed by CSRC.All directors are attended the Board Meeting for report deliberation.Prompt of modified auditing opinion
□ Applicable √ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reportingperiod
□ Applicable √ Not applicable
The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reservesProfit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable √ Not applicable
II. Basic information of the company
1. Company profile
| Short form of the stock | Sinopharm Accord, Accord B | Stock code | 000028, 200028 | |
| Stock exchange for listing | Shenzhen Stock Exchange | |||
| Person/Way to contact | Secretary of the Board | Rep. of security affairs | ||
| Name | Chen Changbing | Wang Zhaoyu | ||
| Office add. | Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province | Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province | ||
| Tel. | +(86)755 25875222 | +(86)755 25875222 | ||
| gyyzinvestor@sinopharm.com | gyyz0028@sinopharm.com | |||
2. Main financial data and index
Whether it has retroactive adjustment or re-statement on previous accounting data
□ Yes √ No
| Current Period | Same period of last year | Increase/decrease in this report y-o-y | |
| Operating revenue (RMB) | 36,128,910,049.98 | 33,163,091,887.39 | 8.94% |
| Net profit attributable to shareholders of the listed Company (RMB) | 674,215,912.93 | 741,445,013.25 | -9.07% |
| Net profit attributable to shareholders of the listed Company after deducting non-recurring gains and losses (RMB) | 652,857,302.76 | 720,954,408.22 | -9.45% |
| Net cash flow arising from operating activities (RMB) | 1,041,664,059.17 | 1,229,373,283.57 | -15.27% |
| Basic earnings per share (RMB/Share) (note 1) | 1.57 | 1.73 | -9.25% |
| Diluted earnings per share (RMB/Share) | 1.57 | 1.73 | -9.25% |
| Weighted average ROE | 4.44% | 5.22% | 0.78percentage points down |
| End of current period | End of last period | Increase/decrease in this report-end over that of last period-end (+,-) | |
| Total assets (RMB) | 45,968,980,824.57 | 42,783,682,431.81 | 7.45% |
| Net assets attributable to shareholder of listed Company (RMB) | 15,342,295,205.24 | 14,924,938,052.50 | 2.80% |
3. Number of shareholders and share-holding
Unit: share
| Total common shareholders at period-end | 43,689 | Total preference shareholders with voting rights recovered at end of reporting period (if applicable) | 0 | ||||
| Top ten shareholders | |||||||
| Full name of Shareholders | Nature of shareholder | Proportion of shares held | Amount of shares held | Amount of restricted shares held | Information of shares pledged, tagged or frozen | ||
| State of share | Amount | ||||||
| Sinopharm Group Co., Ltd. | State-owned Corporation | 56.06% | 239,999,991 | 5,505,770 | |||
| FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND | Foreign Corporation | 2.52% | 10,802,495 | ||||
| Hong Kong Securities Clearing Company Ltd | Foreign Corporation | 1.73% | 7,415,259 | |||
| China National Pharmaceutical Foreign Trade Corp. | State-owned Corporation | 1.24% | 5,323,043 | |||
| National Social Security Fund 413 Portfolio | Domestic non state-owned Corporation | 1.19% | 5,100,032 | |||
| BBH BOS S/A FIDELITY FD - CHINA FOCUS FD | Foreign Corporation | 0.78% | 3,358,761 | |||
| Fidelity Investment Management (Hong Kong) Limited - Client’s fund | Domestic non state-owned Corporation | 0.54% | 2,301,737 | |||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | Domestic non state-owned Corporation | 0.47% | 1,999,227 | |||
| ICBC-Guolian Andesheng Small Selected Securities Investment Fund | Domestic non state-owned Corporation | 0.38% | 1,632,000 | |||
| UBS AG LONDON BRANCH | Foreign Corporation | 0.30% | 1,271,030 |
| Explanation on associated relationship among the aforesaid shareholders | Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies. |
4. Changes of controlling shareholders or actual controller
Changes of controlling shareholders in reporting period
□ Applicable √ Not applicable
Changes of controlling shareholders had no change in reporting period.Changes of actual controller in reporting period
□ Applicable √ Not applicable
Changes of actual controller had no change in reporting period.
5. Total preferred stock shareholders of the Company and shares held by top ten shareholders withpreferred stock heldThe Company had no shareholders with preferred stock held in the reporting.
6. Bonds in existence as of the approval date of the semi-annual report
□ Applicable √ Not applicable
III. Important eventsOn December 29, 2021, Sinopharm Holding Guoda Drugstore Co., Ltd. (hereinafter referred to as "Guoda Drugstore"), acontrolling subsidiary of the Company, entered in to the Letter of Intent for Cooperation on the acquisition of some social retailpharmacy assets of the Company's controlling shareholders with Sinopharm Holding Hubei Co., Ltd. (hereinafter referred to as"Sinopharm Holding Hubei"). For details, please refer to the Sinopharm Accord: Announcement on Related Transactions ofControlling Shareholders' Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social RetailPharmacy Assets" (Announcement No.:2021-42) disclosed on www.cninfo.com.cn dated December 31, 2021 .On June 27, 2022, the seventh meeting of the ninth board of directors of the company reviewed and approved the Proposal onSinopharm Holding Guoda Drugstore Co., Ltd. Entrusting 100% Equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co.,Ltd. and Changing the Way to Solve the Horizontal Competition of Social Retail Pharmacy Assets. The board of directors agreedthat Guoda Drugstore and Sinopharm Holding Hubei sign the Equity Escrow Agreement, changing the original method of solvingthe horizontal competition of social retail pharmacy assets from acquisition to escrow, that is, from Guoda Drugstore purchasing51% equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co., Ltd. to escrowing 100% of its equity. On June 27, 2022, the
two parties formally signed the Equity Escrow Agreement. For details, please refer to the Sinopharm Accord: ProgressAnnouncement on the Controlling Shareholder's Fulfillment of Commitments and Solving the Problem of Horizontal Competitionin Social Retail Pharmacy Assets" (Announcement No.:2022-28) disclosed on www.cninfo.com.cn dated June 29, 2022.
China National Accord Medicines Corporation Ltd.Legal representative: Lin Zhaoxiong
August 31, 2022